# US 2017/0291911 A1 · Ataxia Telengiectasia And RAD3-Related (ATR) Inhibitors And Methods Of Their Use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0291911 A1
- Document ID: US20170291911A1
- Status: Published application
- Kind: A1
- Application number: 15/486,017
- Filed: 2017-04-12
- Published: 2017-10-12
- Earliest claimed: 2016-04-12
- Assignees: Atrin Pharmaceuticals LLC
- Applicants: Atrin Pharmaceuticals LLC
- Inventors: Henry Joseph Breslin; Oren Gilad; Gerhard Sperl; Eric J. Brown; Laura Butler
- Web page: https://patentgrep.com/patent/US20170291911A1

## CPC

- C07D 515/04: Ortho-condensed systems
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The disclosure is directed to compounds and compositions that inhibit Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase and methods of their use.

## Claims

### Claim 1

A compound of Formula (I) or Formula (II):
wherein:
A is CH, C—C1-6alkyl, C—C1-6haloalkyl, or N;
B is CH, C—C1-6alkyl, C—C1-6haloalkyl, or N;
ring D is phenylene or pyridylene;
R11 is H or C1-6alkyl;
R12 is H or C1-6alkyl;
R13 is H or C1-6alkyl;
R14 is OH, —OC1-30alkyl, —O-aryl, —O—C1-30alk-C(O)C1-30alkyl, —O—C1-30alk-C(O)NR15R16, —O-monosaccharide, —S—C1-30alkyl, a peptidyl moiety, an isopeptide moiety, or a peptidyl-isopeptide moiety;
R15 and R16 are, independently, optionally substituted C1-30alkyl, C1-20alkenyl, aryl, arylalkyl, or C3-10cycloalkyl;
Z′ is —SO2— or —C(O)—;
Y′ is an alkylene;
n is 1 or 2;
each J1′ is, independently, H, halogen, optionally substituted —C1-6alkyl, optionally substituted C1-6haloalkyl, optionally substituted —C1-6alkoxy, NH2, NH-(optionally substituted C1-6 alkyl), N-(optionally substituted C1-6alkyl)(optionally substituted C1-6alkyl), —C1-6alk-NH-(optionally substituted C1-6alkyl), or —C1-6alk-NH—C0-6alk-(optionally substituted C3-6heterocycloalkyl); and
L′ is a 7 to 17-membered linking group comprising an alkylene interrupted by 1, 2, 3, 4 or 5 heteroatom moieties selected from —O—, —NH—, —N(C1-6alkyl),
—N(optionally substituted C1-6alkyl), and
—N(C1-6alkyl)-O(optionally substituted C1-6alkyl);
or a pharmaceutically acceptable salt thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of claim 1, wherein R14 is —OH, —S—C1-30alkyl, —OC1-30alkyl, —Oaryl, —O—C1-30alk-C(O)C1-30alkyl, —O—C1-30alk-C(O)N(C1-30alkyl)(C1-30alkyl), or —O-monosaccharide.

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The compound of claim 1, wherein R14 is a peptidyl moiety.

### Claim 6 (depends on 5)

The compound of claim 5, wherein the peptidyl moiety contains 1 to 5 amino acid residues, wherein the amino acids are independently selected from naturally-occurring amino acids and non-naturally-occurring amino acids.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R14 is an isopeptide moiety that is
—NH—C1-10alk-CH(NH2)(C1-10alkyl)OH,
—NH—C1-10alk-CH(NHC1-10alkyl)(C1-10alkyl)OH,
—NH—C1-10alk-CH(N[C1-10alkyl]2)(C1-10alkyl)OH,
—NH—C1-10alk-CH(NH2)(CO—C1-10alkyl),
—NH—C1-10alk-CH(NHC1-10alkyl)(CO—C1-10alkyl),
—NH—C1-10alk-CH(N[C1-10alkyl]2)(CO—C1-10alkyl),
—NH—C1-10alk-CH(NH2)(COO—C1-10alkyl),
—NH—C1-10alk-CH(NHC1-10alkyl)(COO—C1-10alkyl), or
—NH—C1-10alk-CH(N[C1-10alkyl]2)(COO—C1-10alkyl).

### Claim 8 (depends on 1)

The compound of claim 1, wherein R14 is a peptidyl-isopeptide moiety that is
-Q-NH—C1-10alk-CH(NH2)(C1-10alkyl)OH,
-Q-NH—C1-10alk-CH(NHC1-10alkyl)(C1-10alkyl)OH,
-Q-NH—C1-10alk-CH(N[C1-10alkyl]2)(C1-10alkyl)OH,
-Q-NH—C1-10alk-CH(NH2)(CO—C1-10alkyl),
-Q-NH—C1-10alk-CH(NHC1-10alkyl)(CO—C1-10alkyl),
-Q-NH—C1-10alk-CH(N[C1-10alkyl]2)(CO—C1-10alkyl),
-Q-NH—C1-10alk-CH(NH2)(COO—C1-10alkyl),
-Q-NH—C1-10alk-CH(NHC1-10alkyl)(COO—C1-10alkyl), or
-Q-NH—C1-10alk-CH(N[C1-10alkyl]2)(COO—C1-10alkyl), wherein Q is a peptidyl moiety containing 1 to 5 amino acid residues, wherein the amino acid residues are independently selected from naturally-occurring amino acids and non-naturally-occurring amino acids.

### Claim 9 (depends on 8)

The compound of claim 8, wherein the isopeptide moiety is

### Claim 10 (depends on 1)

The compound of claim 1, wherein R14 is —O-monosaccharide, —O-glucuronide, or —O—C1-30alk-C(O)N(C1-30alkyl)(C1-30alkyl).

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The compound of claim 1, wherein A is CH and B is CH.

### Claim 14 (depends on 1)

The compound of claim 1, wherein A is N and B is CH.

### Claim 15 (depends on 1)

The compound of claim 1, wherein A is CH and B is N.

### Claim 16 (depends on 1)

The compound of claim 1, wherein one or both of A and B is C—C1-6alkyl.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The compound of claim 1, wherein one or both of A and B is C—C1-6fluoroalkyl.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The compound of claim 1, wherein R11, R12, and R13 are each H.

### Claim 21 (depends on 1)

The compound of claim 1, wherein Z′ is —SO2—.

### Claim 22 (depends on 1)

The compound of claim 1, wherein Z′ is —C(O)—.

### Claim 23 (depends on 1)

The compound of claim 1, wherein Y′ is a C1-6alkylene.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The compound of claim 1, wherein ring D is phenyl.

### Claim 26 (depends on 1)

The compound of claim 1, wherein ring D is pyridyl.

### Claim 27 (depends on 1)

The compound of claim 1, wherein n is 1.

### Claim 28 (depends on 1)

The compound of claim 1, wherein J1′ is H or —C1-6alkyl or substituted —C1-6alkyl.

### Claim 29

(canceled)

### Claim 30 (depends on 1)

The compound of claim 1, wherein J1′ is —C1-6alk-NH—(C1-6alkyl) or —C1-6alk-NH-(substituted C1-6alkyl).

### Claim 31 (depends on 1)

The compound of claim 1, wherein J1′ is —C1-6alk-NH—C0-6alk-(C3-6heterocycloalkyl) or —C1-6alk-NH—C0-6alk-(substituted C3-6heterocycloalkyl).

### Claim 32 (depends on 1)

The compound of claim 1, wherein L′ is a 7 or 9-membered linking group comprising an alkylene interrupted by three —O— heteroatom moieties.

### Claim 33 (depends on 1)

The compound of claim 1, wherein L′ is a 7 or 9-membered linking group comprising an alkylene interrupted by one —O— heteroatom moiety and one —NH—, —N(C1-6alkyl), —N(optionally substituted C1-6alkyl), or —N(C1-6alkyl)-O(optionally substituted C1-6alkyl) heteroatom moiety.

### Claim 34 (depends on 1)

The compound of claim 1, wherein L′ is a 7 or 9-membered linking group comprising an alkylene interrupted by two —O— heteroatom moieties and one —NH—, —N(C1-6alkyl), —N(optionally substituted C1-6alkyl), or —N(C1-6alkyl)-O(optionally substituted C1-6alkyl) heteroatom moiety.

### Claim 35 (depends on 1)

The compound of claim 1, wherein L′ is —(CH2CH2O)3—, —CH2(CH2CH2O)2—, —CH(CH3)(CH2CH2O)3—, —(CH2CH2CH2O)2—, —CH2CH2NH(CH2CH2O)2, or —O—(CH2CH2O)2—.

### Claim 36 (depends on 1)

The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.

### Claim 37 (depends on 1)

The compound of claim 1 that is
or a pharmaceutically acceptable salt thereof.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 40)

The pharmaceutical composition of claim 40, further comprising an enzyme inhibitor.

### Claim 42

(canceled)

### Claim 43

(canceled)

### Claim 44 (depends on 1)

A method of treating cancer in a patient comprising administering to the patient a compound of claim 1.

### Claim 45 (depends on 44)

The method of claim 44, wherein the compound is administered in combination with another therapeutic chemotherapy agent.

### Claim 46 (depends on 44)

The method of claim 44, wherein the compound is administered in combination with an enzyme inhibitor.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49 (depends on 44)

The method of claim 44, wherein the cancer is breast cancer, prostate cancer, pancreatic cancer, lung cancer, colorectal cancer, ovarian cancer, liver cancer, melanoma, renal cancer, a central nervous system cancer, brain cancer, glioblastoma, a leukemia, or a lymphoma.

### Claim 50 (depends on 44)

The method of claim 44, wherein the cancer is ocular melanoma, desmoplastic round cell tumor, chondrosarcoma, leptomengial disease, diffuse large B-cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, an AIDS-related cancer, an AIDS-related lymphoma, anal or rectal cancer, appendix cancer, astrocytomas, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, osteosarcoma or malignant fibrous histiocytoma, brain tumor, breast cancer, prostate cancer, bronchial tumor, Burkitt lymphoma, spinal cord tumor, carcinoid tumor, carcinoma of unknown primary, central nervous system atypical teratoid/rhabdoid tumor, leptomeningeal disease, central nervous system embryonal tumors, central nervous system lymphoma, cervical cancer, chordoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative, disorders, colon cancer, colorectal cancer, craniopharyngioma, cutaneous T-Cell lymphoma, endometrial cancer, ependymoblastoma, ependymoma, esophageal cancer, a Ewing sarcoma family tumor, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, gallbladder cancer, gastric (stomach) cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal Tumor (GIST), germ cell tumor, gestational trophoblastic tumor, glioma, hairy cell leukemia, head or neck cancer, hepatocellular (liver) cancer, histiocytosis, Hodgkin's lymphoma, hypopharyngeal cancer, Kaposi sarcoma, kidney (renal cell) cancer, Langerhan's cell histiocytosis, laryngeal cancer, lip or oral cavity cancer, liver cancer, lung cancer, Non-Hodgkin's lymphoma, primary central nervous system lymphoma, Waldenström's macroglobulinemia (lymphoplasmacytic lymphoma), medulloblastoma, medulloepithelioma, melanoma, merkel cell carcinoma, mesothelioma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia syndrome, mouth cancer, multiple myeloma/plasma cell neoplasm, mycosis fungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms, multiple myeloma, myeloproliferative disorder, nasal cavity or paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, osteosarcoma or malignant fibrous histiocytoma of bone, ovarian cancer, ovarian germ cell tumor, ovarian epithelial cancer, ovarian low malignant potential tumor, pancreatic cancer, papillomatosis, paranasal sinus or nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pineal parenchymal tumors of intermediate differentiation, pineoblastoma or supratentorial primitive neuroectodermal tumors, pituitary tumor, pleuropulmonary blastoma, pregnancy or breast cancer, prostate cancer, rectal cancer, renal pelvis or ureter cancer, respiratory tract carcinoma involving the NUT gene on chromosome 15, retinoblastoma, rhabdomyosarcoma, high grade prostate cancer, medium grade prostate cancer, low grade prostate cancer, castration-resistant prostate cancer, salivary gland cancer, sarcoma, Sézary syndrome, skin cancer, ocular cancer, skin carcinoma, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, squamous neck cancer with occult primary, supratentorial primitive neuroectodermal tumors, T-Cell lymphoma, testicular cancer, throat cancer, thymoma or thymic carcinoma, thyroid cancer, transitional cell cancer of the renal pelvis or ureter, gestational trophoblastic tumor, cancer of unknown primary site such as carcinoma of unknown primary site, unusual cancers of childhood, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Wilm's tumor, or a women's cancer.
